PHOENIX, June 13, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire welcomed Andy Whelan, President of BioElectronics
Corporation (OTC Pink:BIEL) (“the Company”) back onto the “Stock Day” podcast. Andy spoke with Everett about their progress in the
US market, UK market, the new product, the US FDA, and new distributors and potential partnership opportunities.
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of
disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal
complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information,
please visit www.bielcorp.com
The Company is currently pursuing multiple US partnership opportunities that are partially contingent on additional FDA
clearance for the treatment of musculoskeletal pain, back pain, knee pain, muscle, hip, carpal tunnel, etc. Whelan said,“Patience
is key throughout this process. It’s going as well as it can.” Additionally, the Company anticipates solidifying deals with two new
major distributors in the Asian and Eastern European markets.
The Company’s product development and regulatory clearances are going well. Now, with pre-submission clearance, the 510(k)
relief of musculoskeletal pain market clearance application will be filed by the end of June.
The US FDA has recently implemented an Innovation Program seeking “Breakthrough Devices” to
Prevent and Treat Opioid Use Disorder. Opioids are routinely used for post-operative pain. Our United
Kingdom ActiPatch User Registry accounts that 71% of opioid customers report a moderate (50%) to complete (100%) elimination in
opioid medication use. The Company plans to submit its post-operative pain relief market clearance application into this
program. The FDA’s assistance, participation, and approval will provide credence and accelerate product market acceptance.
The Company has begun shipments of its new single box kinesiology tape product to be used for back, knee, hip, and muscles and
joints in lieu of the back wrap, knee wrap and muscle and joint adhesives. The kinesiology tape is easier to use, reduces
product costs, and retail shelf space requirements.
The Company is transitioning its United Kingdom over-the-counter sales and marketing from the front of the store to behind the
counter to expand product availability from a few stores to all 14,000 pharmacies. Most pharmacies obtain daily product deliveries
and most people in the UK qualify for free prescriptions.
Whelan is confident in the direction the Company is moving, and cites the unique nature of their products as a factor that helps
the Company stand out in the global medical electronics industry. Whelan then said, “This is one busy little Company.”
“Stock Day” host Everett Jolly stands by his assessment from his April interview with the company that the stock is very
undervalued. BioElectronics Corporation trades on the OTC Pink market under the ticker symbol BIEL. Shares are currently selling at
0.0037, up over 100% since April.
For more details about the Company’s recent FDA meetings, potential partnership opportunities, and attempts to combat the
ongoing opioid crisis, follow the link below to hear the full interview.
https://upticknewswire.com/featured-interview-ceo-andrew-whelan-of-bioelectronics-corp-otc-pink-biel-3/
About BioElectronics Corporation
BioElectronics develops and manufactures unique nonprescription affordable neuromodulation medical devices. The Company’s
technology platform is for the treatment of central sensitization, which is now widely accepted as the physiological explanation
for many neurological disorders, and specifically chronic pain. Central sensitization is difficult, if not impossible, to address
through pharmacotherapy without having a detrimental impact on normal physiologic function. Moreover, pharmacological and masking
therapies (creams, heat patches, TENS etc.) have limited effectiveness for chronic pain due to their transient nature.
BioElectronics’ electromagnetic stimulation therapy has the distinct advantage of being safe, affordable, long lasting, and
effective pain relief.
Contact: Paul Knopick, 940.262.3584, pknopick@eandecommunications.com
Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates, and projections and,
consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,”
“estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,”
“predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward looking statements. These
forward-looking statements, involve significant risks and uncertainties that could cause actual results to differ materially from
the expected results.
About Uptick Newswire and the “Stock Day” Podcast
Uptick Newswire is a private company reaching out to the masses to keep investors and shareholders involved and up to date on
company news, and bringing transparency to under-valued, undersold micro-cap stocks of the market, and is the sole producer of the
Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently
launched the Video Interview Studio located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message
board at https://investorshangout.com/
